The new extended-release formulation of Xeljanz, Xeljanz XR, has started its landing process in general hospitals.

According to industry sources, Pfizer Korea’s rheumatoid arthritis treatment ‘Xeljanz XR 11mg’ passed the Drug Committees (DCs) of the Big-5s general hospitals in Korea - Seoul National University Hospital (SNUH), Asan Medical Center (AMC), Seoul St. Mary’s Hospital, Samsung Medical Center (SMC), and Severance Hospital – as well as other major medical institutions in the nation.

Xeljanz XR, which was listed for insurance benefit since April last year, can be used in adult rheumatoid arthritis patients that meet the ACR/EULAR criteria whose: ▲DAS28 is mor